Detalhe da pesquisa
1.
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
N Engl J Med
; 388(19): 1767-1778, 2023 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163623
2.
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Lancet
; 401(10379): 821-832, 2023 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774933
3.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 384(9): 829-841, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33657295
4.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
; 381(21): 2020-2031, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562796
5.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(2): 198-211, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33476593
6.
Detection of somatic mutations in ctDNA derived from adenocarcinoma patients - EGFR tyrosine kinase inhibitor monitoring preliminary study.
Contemp Oncol (Pozn)
; 23(2): 87-91, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31316290
7.
A systemic literature review of neuroimaging studies in women with breast cancer treated with adjuvant chemotherapy.
Contemp Oncol (Pozn)
; 21(1): 6-15, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28435392
8.
Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions.
Int J Mol Sci
; 17(11)2016 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27834917
9.
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
J Immunother Cancer
; 12(2)2024 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38346853
10.
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.
Target Oncol
; 18(5): 639-641, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37659025
11.
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
J Clin Oncol
; 41(12): 2166-2180, 2023 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36473143
12.
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Eur J Cancer
; 183: 174-187, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36871487
13.
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol
; 41(18): 3339-3351, 2023 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36952634
14.
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
J Thorac Oncol
; 18(8): 1055-1069, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37146754
15.
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
J Thorac Oncol
; 18(1): 79-92, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36049658
16.
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry.
Eur Urol Open Sci
; 45: 12-22, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36353661
17.
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
J Thorac Oncol
; 17(2): 289-308, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34648948
18.
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1.
J Thorac Oncol
; 16(4): 665-676, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33485960
19.
Verbal fluency in breast cancer patients treated with chemotherapy.
Breast Cancer
; 24(3): 376-383, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27435227
20.
[The assessment of temperament, quality of life and intensity of depressive symptoms in patients with Hodgkin's disease in different stages of the illness]. / Ocena temperamentu, jakosci zycia i nasilenia cech depresji u pacjentów z choroba Hodgkina w jej róznych fazach.
Psychiatr Pol
; 39(4): 679-90, 2005.
Artigo
em Polonês
| MEDLINE | ID: mdl-16237973